REFERENCES
- Pharmaceutical Research and Manufacturers of America. Pharmaceutical Industry Profile 2005, PhRMA, Washington, DC March, 2005; 4–5
- U.S. Food and Drug Administration Center for Drug Evaluation and Research. From test tube to patient: improving health through human drugs. Food and Drug Administration, Rockville, MD September, 1999; 21, Accessed online August 11, 2005: http://www.fda.gov/cder
- Pharmaceutical Research and Manufacturors of America. Pharmaceutical Industry Profile 2000, PhRMA, Washington, DC 2000; 35
- Food and Drug Administration, Online: http://www.fda.gov/cder/rdmt/pstable.htm, Accessed August 11, 2005
- Horstmann E., McCabe M. S., Grochow L., et al. Risks and benefits of phase I oncology trials, 1991 through 2002. N. Engl. J. Med. 2005; 352: 895–904, [PUBMED], [INFOTRIEVE], [CSA]
- Thezenas S., Duffour J., Culine S., Kramar A. Five-year change in statistical designs of phase II trials published in leading cancer journals. Eur. J. Cancer 2004; 40: 1244–1249, [INFOTRIEVE], [CROSSREF], [CSA]
- Simon R., Wittes R. E., Ellenberg S. S. Randomized phase II clinical trials. Cancer Treat. Rep. 1985; 69: 1375–1381, [INFOTRIEVE], [CSA]
- Estey E. H., Thall P. F. New designs for phase 2 clinical trials. Blood 2003; 102: 442–448, [INFOTRIEVE], [CROSSREF], [CSA]
- Liu P. Y., LeBlanc M., Desai M. False positive rates of randomized phase II designs. Control Clin Trials 1999; 20: 343–352, [INFOTRIEVE], [CROSSREF], [CSA]
- Perrone F., Di Maio M., De Maio E., et al. Statistical design in phase II clinical trials and its application in breast cancer. Lancet 2003; 4: 305–311, [CROSSREF], [CSA]
- Therasse P., Arbuck S. G., Eisenhauer E. A., et al. New guidelines to evaluate the response to treatment in solid tumors. J. Natl. Cancer Inst. 2000; 92: 205–216, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Mick R., Crowley J. J., Carroll R. J. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. Control Clin. Trials 2000; 21: 343–359, [INFOTRIEVE], [CROSSREF], [CSA]
- Korn E. L., Arbuck S. G., Pluda J. M., et al. Clinical trial designs for cytostatic agents: Are new approaches needed?. J. Clin. Oncol. 2001; 19: 265–272, [PUBMED], [INFOTRIEVE], [CSA]
- Green S., Benedetti J., Crowley J. Clinical Trials in Oncology, 2nd ed. Chapman & Hall/CRC, New York 2003; 65: 54–58
- Simon R. M., Steinberg S. M., Hamilton M., et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J. Clin. Oncol. 2001; 15: 1848–1854, [CSA]
- Hoekstra R., Verweij J., Eskens-Ferry A. L.M. Clinical trial design for target specific anticancer agents. Investigational New Drugs 2003; 21: 243–250, [INFOTRIEVE], [CROSSREF], [CSA]
- Gehan E. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J. Chron. Dis. 1961; 13: 346–353, [INFOTRIEVE], [CROSSREF], [CSA]
- Fleming T. R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143–151, [INFOTRIEVE], [CSA]
- Simon R. Optimal two-stage designs for phase II clinical trials. Contr. Clin. Trials 1989; 10: 1–10, [CROSSREF], [CSA]
- Rubinstein L. V. Therapeutic studies Hematol/Oncol. Clinics North America 2000; 14: 849–876, [CSA]
- Cornfield J. Sequential trials, sequential analysis and the likelihood principle. Amer. Statist. 1966; 20: 18–23, [CROSSREF], [CSA]
- Cornfield J. The Bayesian outlook and its application. Biometrics 1969; 25: 617–657, [INFOTRIEVE], [CSA]
- Royall R. Statistical Evidence: A Likelihood Paradigm. Chapman & Hall/CRC, New York 1997
- Ensign L. G., Gehan E. A., Kamen D. S., Thall P. F. An optimal three-stage design for phase II clinical trials. Stat. Med. 1994; 13: 1727–1736, [INFOTRIEVE], [CSA]
- Chen T. T. Optimal three-stage design for phase II clinical trials. Stat. Med. 1997; 16: 2701–2711, [INFOTRIEVE], [CROSSREF], [CSA]
- Schultz J. R., Nichol F. R., Elfring G. L., Weed S. D. Multiple-stage procedures for drug screening. Biometrics 1973; 29: 293–300, [INFOTRIEVE], [CSA]
- Fleming T. R., Harrington D. P., O'Brien P. C. Designs for group sequential tests. Control Clin. Trials 1984; 5: 348–361, [INFOTRIEVE], [CROSSREF], [CSA]
- Atkinson E. N., Brown B. W. Confidence limits for probability of response in multistage phase II clinical trials. Biometrics 1985; 41: 741–744, [INFOTRIEVE], [CSA]
- Chang M. N., Therneau T. M., Wieand H. S., Cha S. S. Designs for group sequential phase II clinical trials. Biometrics 1987; 43: 865–874, [INFOTRIEVE], [CSA]
- Duffy D. E., Santner T. J. Confidence intervals for a binomial parameter based on multistage tests. Biometrics 1987; 43: 81–94, [CSA]
- Jennison C., Turnbull B. W. Group Sequential Designs with Applications to Clinical Trials. Chapman & Hall/CRC, Boca Raton 2000
- Herndon J. E. A design alternative for two-stage, phase II, multicenter cancer clinical trials. Control Clin. Trials 1998; 19: 440–450, [INFOTRIEVE], [CROSSREF], [CSA]
- Bryant J., Day R. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics 1995; 51: 1372–1383, [INFOTRIEVE], [CSA]
- Thall P. F., Simon R., Estey E. H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat. Med. 1995; 14: 357–379, [INFOTRIEVE], [CSA]
- Thall P. F., Simon R. M., Estey E. H. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J. Clin. Oncol. 1996; 14: 296–303, [INFOTRIEVE], [CSA]
- Case L. D., Morgan T. M. Design of phase II cancer trials evaluating survival probabilities. BMC Medical Research Methodology 2003; 3: 6, [INFOTRIEVE], [CROSSREF], [CSA]
- Aalen O. O. Nonparametric inference for a family of counting processes. Ann. Stat. 1978; 6: 701–726, [CSA]
- Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc. 1958; 53: 457–481, [CROSSREF], [CSA]
- Fayers P. M., Ashby D., Parmar M. K.B. Tutorial in biostatistics. Bayesian data monitoring in clinical trials. Stat. Med. 1997; 16: 1413–1430, [INFOTRIEVE], [CROSSREF], [CSA]
- Heitjan D. F. Bayesian interim analysis of phase II cancer clinical trials. Stat. Med. 1997; 16: 1791–1802, [INFOTRIEVE], [CROSSREF], [CSA]
- Spieghhalter D. J., Freedman L. S., Parmar M. K.B. Bayesian approaches to randomized trials. J. Roy. Statist. Soc. Series A 1999; 157: 357–416, [CSA]
- Berry D. A. Bayesian statistics and the efficiency and ethics of clinical trials. Stat. Science 2004; 19: 175–187, [CROSSREF], [CSA]
- Lee P. M. Bayesian Statistics: An Introduction, 3rd Ed. Edward Arnold, London 2004
- Thall P. F., Simon R. A Bayesian approach to establishing sample size and monitoring criteria for phase II clinical trials. Control Clin. Trials 1994; 15: 463–481, [INFOTRIEVE], [CROSSREF], [CSA]
- Tan S. B., Machin D. Bayesian two-stage designs for phase II clinical trials. Stat. Med. 2002; 21: 1991–2012, [INFOTRIEVE], [CROSSREF], [CSA]
- Mayo M. S., Gajewski B. J. Bayesian sample size calculations in phase II clinical trials using informative conjugate priors. Control Clin. Trials 2004; 25: 157–167, [INFOTRIEVE], [CROSSREF], [CSA]